nach oben

Breast Cancer Research and Treatment

Erschienen in:

01.01.2008 | Preclinical Study

Prophylactic IL-12 treatment reduces postoperative metastasis: mediation by increased numbers but not cytotoxicity of NK cells

verfasst von: Yossi Schwartz, Roi Avraham, Marganit Benish, Ella Rosenne, Shamgar Ben-Eliyahu

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 2/2008

Einloggen, um Zugang zu erhalten

Abstract

Despite a promising potential, interleukin-12 immunotherapy has yielded limited clinical success while causing perilous toxicities. Here we study a context in which IL-12 may prove clinically beneficial—the removal of the primary tumor, when cell-mediated immunity (CMI) may eradicate minimal residual disease (MRD), but is inhibited by postoperative immunosuppression, potentially leading to enhanced malignant progression. F344 rats were preoperatively treated with IL-12 and inoculated postoperatively with syngeneic MADB106 tumor cells. An optimal regimen of eight-day sustained exposure to IL-12 was developed (1 μg/rat/day), which caused mild side effects, increased baseline resistance to experimental MADB106 metastasis, and abolished the promotion of metastasis by laparotomy and other immunosuppressive paradigms. Depletion of NK cells indicated their major role in controlling MADB106 metastasis in naïve and IL-12 treated rats. Studying NK cytotoxicity, we found that IL-12 did not potentiate activity per NK cell, nor protected it from suppression by surgery. However, IL-12 increased the numbers of NK cells in the circulation and marginating pulmonary pool of naïve and operated rats, and correspondingly increased total NK activity in these compartments. Therefore, this study indicates anti-tumor effects of IL-12 based on increased numbers of strategically located NK cells, and advocates a prophylactic approach against the potential metastasis-promoting effects of surgery.

Brunda MJ, Luistro L, Warrier RR et al (1993) Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 178:1223–1230PubMedCrossRef

Boggio K, Di Carlo E, Rovero S et al (2000) Ability of systemic interleukin-12 to hamper progressive stages of mammary carcinogenesis in HER2/neu transgenic mice. Cancer Res 60:359–364PubMed

Smyth MJ, Taniguchi M, Street SE (2000) The anti-tumor activity of IL-12: mechanisms of innate immunity that are model and dose dependent. J Immunol 165:2665–2670PubMed

Kobayashi T, Shiiba K, Satoh M et al (2002) Interleukin-12 administration is more effective for preventing metastasis than for inhibiting primary established tumors in a murine model of spontaneous hepatic metastasis. Surg Today 32:236–242PubMedCrossRef

Zou JP, Yamamoto N, Fujii T et al (1995) Systemic administration of rIL-12 induces complete tumor regression and protective immunity: response is correlated with a striking reversal of suppressed IFN-gamma production by anti-tumor T cells. Int Immunol 7:1135–1145PubMedCrossRef

Nastala CL, Edington HD, McKinney TG et al (1994) Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J Immunol 153:1697–1706PubMed

Colombo MP, Trinchieri G (2002) Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev 13:155–168PubMedCrossRef

Caminschi I, Venetsanakos E, Leong CC et al (1998) Interleukin-12 induces an effective antitumor response in malignant mesothelioma. Am J Respir Cell Mol Biol 19:738–746PubMed

Cui J, Shin T, Kawano T et al (1997) Requirement for Valpha14 NKT cells in IL-12-mediated rejection of tumors. Science 278:1623–1626PubMedCrossRef

10.

Hurteau JA, Blessing JA, DeCesare SL et al (2001) Evaluation of recombinant human interleukin-12 in patients with recurrent or refractory ovarian cancer: a gynecologic oncology group study. Gynecol Oncol 82:7–10PubMedCrossRef

11.

Atkins MB, Robertson MJ, Gordon M et al (1997) Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res 3:409–417PubMed

12.

Portielje JE, Kruit WH, Schuler M et al (1999) Phase I study of subcutaneously administered recombinant human interleukin 12 in patients with advanced renal cell cancer. Clin Cancer Res 5:3983–3989PubMed

13.

Leonard JP, Sherman ML, Fisher GL et al (1997) Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood 90:2541–2548PubMed

14.

Rook AH, Wood GS, Yoo EK et al (1999) Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses. Blood 94:902–908PubMed

15.

Shakhar G, Ben-Eliyahu S (2003) Potential prophylactic measures against postoperative immunosuppression: could they reduce recurrence rates in oncological patients? Ann Surg Oncol 10:972–992PubMedCrossRef

16.

Brittenden J (1996) Natural killer cells and cancer. Cancer 77:1226–1243PubMedCrossRef

17.

Ben-Eliyahu S, Page GG, Yirmiya R et al (1999) Evidence that stress and surgical interventions promote tumor development by suppressing natural killer cell activity. Int J Cancer 80:880–888PubMedCrossRef

18.

Dithmar SA, Rusciano DA, Armstrong CA et al (1999) Depletion of NK cell activity results in growth of hepatic micrometastases in a murine ocular melanoma model. Curr Eye Res 19:426–431PubMedCrossRef

19.

Smyth MJ, Godfrey DI, Trapani JA (2001) A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol 2:293–299PubMedCrossRef

20.

Taketomi A, Shimada M, Shirabe K et al (1998) Natural killer cell activity in patients with hepatocellular carcinoma: a new prognostic indicator after hepatectomy. Cancer 83:58–63PubMedCrossRef

21.

Schantz SP, Brown BW, Lira E et al (1987) Evidence for the role of natural immunity in the control of metastatic spread of head and neck cancer. Cancer Immunol Immunother 25:141–148PubMedCrossRef

22.

Ben-Eliyahu S, Page GG, Yirmiya R et al (1996) Acute alcohol intoxication suppresses natural killer cell activity and promotes tumor metastasis. Nat Med 2:457–460PubMedCrossRef

23.

Ben-Eliyahu S, Page GG (1992) In vivo assessment of natural killer cell activity in rats. Prog Neuroendocrinemmunol 5:199–214

24.

Barlozzari T, Leonhardt J, Wiltrout RH et al (1985) Direct evidence for the role of LGL in the inhibition of experimental tumor metastases. J Immunol 134:2783–2789PubMed

25.

Shakhar G, Ben-Eliyahu S (1998) In vivo beta-adrenergic stimulation suppresses natural killer activity and compromises resistance to tumor metastasis in rats. J Immunol 160:3251–3258PubMed

26.

Ben-Eliyahu S, Yirmiya R, Liebeskind JC et al (1991) Stress increases metastatic spread of a mammary tumor in rats: evidence for mediation by the immune system. Brain Behav Immun 5:193–205PubMedCrossRef

27.

Melamed R, Rosenne E, Shakhar K et al (2005) Marginating pulmonary-NK activity and resistance to experimental tumor metastasis: suppression by surgery and the prophylactic use of a beta-adrenergic antagonist and a prostaglandin synthesis inhibitor. Brain Behav Immun 19:114–126PubMedCrossRef

28.

Barlozzari T, Reynolds CW, Herberman RB (1983) In vivo role of natural killer cells: involvement of large granular lymphocytes in the clearance of tumor cells in anti-asialo GM1-treated rats. J Immunol 131:1024–1027PubMed

29.

Bar-Yosef S, Melamed R, Page GG et al (2001) Attenuation of the tumor-promoting effect of surgery by spinal blockade in rats. Anesthesiology 94:1066–1073PubMedCrossRef

30.

Dengler HG, Hengstmann JH (1976) Metabolism and pharmacokinetics of orciprenaline in various animal species and man. Arch Int Pharmacodyn Ther 223:71–87PubMed

31.

Zuckerman L, Rimmerman N, Weiner I (2003) Latent inhibition in 35-day-old rats is not an “adult” latent inhibition: implications for neurodevelopmental models of schizophrenia. Psychopharmacology (Berl) 169:298–307CrossRef

32.

Chambers WH, Brumfield AM, Hanley-Yanez K et al (1992) Functional heterogeneity between NKR-P1^bright/Lycopersicon esculentum lectin (L.E.)^brightand NKR-P1^bright/L.E.^dim subpopulations of rat natural killer cells. J Immunol 148:3658–3665PubMed

33.

Chambers WH, Vujanovic NL, DeLeo AB et al (1989) Monoclonal antibody to a triggering structure expressed on rat natural killer cells and adherent lymphokine-activated killer cells. J Exp Med 169:1373–1389PubMedCrossRef

34.

Page GG, Ben-Eliyahu S, Liebeskind JC (1994) The role of LGL/NK cells in surgery-induced promotion of metastasis and its attenuation by morphine. Brain Behav Immun 8:241–250PubMedCrossRef

35.

Ben-Eliyahu S, Page GG, Shakhar G et al (1996) Increased susceptibility to metastasis during pro-oestrus/oestrus in rats: possible role of oestradiol and natural killer cells. Br J Cancer 74:1900–1907PubMed

36.

Fishkin RJ, Winslow JT (1997) Endotoxin-induced reduction of social investigation by mice: interaction with amphetamine and anti-inflammatory drugs. Psychopharmacology (Berl). 132:335–341CrossRef

37.

Yirmiya R, Tio DL, Taylor AN (1996) Effects of fetal alcohol exposure on fever, sickness behavior, and pituitary-adrenal activation induced by interleukin-1 beta in young adult rats. Brain Behav Immun 10:205–220PubMedCrossRef

38.

Yirmiya R, Pollak Y, Morag M et al (2000) Illness, cytokines, and depression. Ann NY Acad Sci 917:478–487PubMedCrossRef

39.

Katafuchi T, Kondo T, Yasaka T et al (2003) Prolonged effects of polyriboinosinic:polyribocytidylic acid on spontaneous running wheel activity and brain interferon-alpha mRNA in rats: a model for immunologically induced fatigue. Neuroscience 120:837–845PubMedCrossRef

40.

Ben-Eliyahu S, Shakhar G, Page GG et al (2000) Suppression of NK cell activity and of resistance to metastasis by stress: a role for adrenal catecholamines and beta-adrenoceptors. Neuroimmunomodulation 8:154–164PubMedCrossRef

41.

Kanaoka E, Takahashi K, Yoshikawa T et al (2002) A significant enhancement of therapeutic effect against hepatic metastases of M5076 in mice by a liposomal interleukin-2 (mixture). J Control Release 82:183–187PubMedCrossRef

42.

Kedar E, Braun E, Rutkowski Y et al (1994) Delivery of cytokines by liposomes. II. Interleukin-2 encapsulated in long-circulating sterically stabilized liposomes: immunomodulatory and anti-tumor activity in mice. J Immunother Emphasis Tumor Immunol 16:115–124PubMed

43.

Liu L, Sakaguchi T, Kanda T et al (2003) Delivery of interleukin-12 in gelatin hydrogels effectively suppresses development of transplanted colonal carcinoma in mice. Cancer Chemother Pharmacol 51:53–57PubMedCrossRef

44.

Gately MK, Desai BB, Wolitzky AG et al (1991) Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic lymphocyte maturation factor). J Immunol 147:874–882PubMed

45.

Robertson MJ, Soiffer RJ, Wolf SF et al (1992) Response of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): cytolytic activity and proliferation of NK cells are differentially regulated by NKSF. J Exp Med 175:779–788PubMedCrossRef

46.

Eng VM, Car BD, Schnyder B et al (1995) The stimulatory effects of interleukin (IL)-12 on hematopoiesis are antagonized by IL-12-induced interferon gamma in vivo. J Exp Med 181:1893–1898PubMedCrossRef

47.

Gately MK, Warrier RR, Honasoge S et al (1994) Administration of recombinant IL-12 to normal mice enhances cytolytic lymphocyte activity and induces production of IFN-gamma in vivo. Int Immunol 6:157–167PubMedCrossRef

48.

Matsumoto G, Omi Y, Lee U et al (2000) Adhesion mediated by LFA-1 is required for efficient IL-12-induced NK and NKT cell cytotoxicity. Eur J Immunol 30:3723–3731PubMedCrossRef

49.

Kawamura T, Takeda K, Mendiratta SK et al (1998) Critical role of NK1+ T cells in IL-12-induced immune responses in vivo. J Immunol 160:16–19PubMed

50.

Lasek W, Golab J, Maslinski W et al (1999) Subtherapeutic doses of interleukin-15 augment the antitumor effect of interleukin-12 in a B16F10 melanoma model in mice. Eur Cytokine Netw 10:345–356PubMed

51.

Okuno K, Jinnai H, Lee YS et al (1996) Interleukin 12 augments the liver-associated immunity and reduces liver metastases. Hepatogastroenterology 43:1196–1202PubMed

52.

Gan X, Zhang L, Solomon GF et al (2002) Mechanism of norepinephrine-mediated inhibition of human NK cytotoxic functions: inhibition of cytokine secretion, target binding, and programming for cytotoxicity. Brain Behav Immun 16:227–246PubMedCrossRef

53.

Mitsuhashi M, Liu J, Cao S et al (2004) Regulation of interleukin-12 gene expression and its anti-tumor activities by prostaglandin E2 derived from mammary carcinomas. J Leukoc Biol 76:322–332PubMedCrossRef

54.

Panina-Bordignon P, Mazzeo D, Lucia PD et al (1997) Beta2-agonists prevent Th1 development by selective inhibition of interleukin 12. J Clin Invest 100:1513–1519PubMedCrossRef

55.

Pockaj BA, Basu GD, Pathangey LB et al (2004) Reduced T-cell and dendritic cell function is related to cyclooxygenase-2 overexpression and prostaglandin E2 secretion in patients with breast cancer. Ann Surg Oncol 11:328–339PubMedCrossRef

56.

Ben-Eliyahu S (2003) The promotion of tumor metastasis by surgery and stress: Immunological basis and implications for psychoneuroimmunology. Brain Behav Immun 17:27–36CrossRef

57.

Dithmar S, Rusciano D, Lynn MJ et al (2000) Neoadjuvant interferon alfa-2b treatment in a murine model for metastatic ocular melanoma: a preliminary study. Arch Ophthalmol 118:1085–1089PubMed

58.

Gallagher WJ, Dubinett SM, Hoover HC Jr et al (1989) Efficacy of adjuvant interleukin-2 after excision of BALB/c fibrosarcomas. Surgery 106:120–125PubMed

59.

Mu J, Zou JP, Yamamoto N et al (1995) Administration of recombinant interleukin 12 prevents outgrowth of tumor cells metastasizing spontaneously to lung and lymph nodes. Cancer Res 55:4404–4408PubMed

60.

Strohlein MA, Grutzner KU, Schildberg FW et al (2002) Induction of cytotoxicity against autologous tumour cells by interleukin-12: evidence for intrinsic anti-tumor immune capacity in curatively resected gastrointestinal tumour patients. Cancer Immunol Immunother 51:505–512PubMedCrossRef

61.

Brivio F, Lissoni P, Alderi G et al (1996) Preoperative interleukin-2 subcutaneous immunotherapy may prolong the survival time in advanced colorectal cancer patients. Oncology 53:263–268PubMedCrossRef

62.

Brivio F, Lissoni P, Fumagalli L et al (1999) Pre-operative IL-2 immunoprophylaxis of cancer recurrence: long-term clinical results of a phase II study in radically operable colorectal cancer. Oncol Rep 6:1205–1207PubMed

63.

Deehan DJ, Heys SD, Ashby J et al (1995) Interleukin-2 (IL-2) augments host cellular immune reactivity in the perioperative period in patients with malignant disease. Eur J Surg Oncol 21:16–22PubMedCrossRef

64.

Luksch R, Perotti D, Cefalo G et al (2003) Immunomodulation in a treatment program including pre- and post-operative interleukin-2 and chemotherapy for childhood osteosarcoma. Tumori 89:263–268PubMed

65.

Coughlin CM, Salhany KE, Gee MS et al (1998) Tumor cell responses to IFNgamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity 9:25–34PubMedCrossRef

66.

Dias S, Boyd R, Balkwill F (1998) IL-12 regulates VEGF and MMPs in a murine breast cancer model. Int J Cancer 78:361–365PubMedCrossRef

67.

Voest EE, Kenyon BM, O’Reilly MS et al (1995) Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 87:581–586PubMedCrossRef

Titel: Prophylactic IL-12 treatment reduces postoperative metastasis: mediation by increased numbers but not cytotoxicity of NK cells
verfasst von: Yossi Schwartz
Roi Avraham
Marganit Benish
Ella Rosenne
Shamgar Ben-Eliyahu
Publikationsdatum: 01.01.2008
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 2/2008
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-007-9540-9

Springer Medizin

Prophylactic IL-12 treatment reduces postoperative metastasis: mediation by increased numbers but not cytotoxicity of NK cells

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2008

ATM allelic variants associated to hereditary breast cancer in 94 Chilean women: susceptibility or ethnic influences?

SUMO and estrogen receptors in breast cancer

Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: a study of 4,444 cases

EZH2 regulates the transcription of estrogen-responsive genes through association with REA, an estrogen receptor corepressor

Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study

Correlation of levels and patterns of genomic instability with histological grading of invasive breast tumors

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie